B. Riley Comments on MiNK Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:INKT)
B. Riley Comments on MiNK Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:INKT)
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Investment analysts at B. Riley issued their Q2 2023 earnings per share (EPS) estimates for shares of MiNK Therapeutics in a note issued to investors on Monday, November 14th. B. Riley analyst K. Patel expects that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($0.84) per share.
水貂治疗公司(纳斯达克:iNKT-GET评级)-B.Riley的投资分析师在11月14日星期一发给投资者的一份报告中发布了他们对水貂治疗公司股票2023年第二季度每股收益的估计。B.Riley分析师K.Patel预计,该公司本季度每股收益将达到0.22美元。对水貂治疗公司目前全年收益的普遍估计为每股0.84美元。
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04.
水貂治疗公司(纳斯达克代码:iNKT-GET Rating)最近一次发布季度收益数据是在11月3日星期四。该公司公布了本季度每股收益(EPS)(0.19美元),比普遍预期的(0.23美元)高0.04美元。
MiNK Therapeutics Stock Performance
水貂治疗公司股票表现
MiNK Therapeutics stock opened at $3.07 on Tuesday. MiNK Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $21.40. The company has a market capitalization of $103.67 million and a P/E ratio of -3.93. The stock has a 50-day simple moving average of $2.26 and a 200-day simple moving average of $1.91.
水貂治疗公司的股票周二开盘报3.07美元。水貂治疗公司的股价为1.09美元,为52周低点,52周高点为21.40美元。该公司市值为1.0367亿美元,市盈率为-3.93倍。该股的50日简单移动均线切入位在2.26美元,200日简单移动均线切入位在1.91美元。
Hedge Funds Weigh In On MiNK Therapeutics
对冲基金入股水貂治疗公司
An institutional investor recently bought a new position in MiNK Therapeutics stock. First Republic Investment Management Inc. purchased a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned 0.24% of MiNK Therapeutics at the end of the most recent reporting period. 1.07% of the stock is currently owned by institutional investors.
一家机构投资者最近买入了水貂治疗公司股票的新头寸。根据第一共和国投资管理公司在第三季度购买了水貂治疗公司(纳斯达克:iNKT-GET评级)的新头寸,根据该公司在最近提交给美国证券交易委员会的13F文件中。该机构投资者购买了81,500股该公司股票,价值约172,000美元。First Republic Investment Management Inc.在最近的报告期结束时拥有水貂治疗公司0.24%的股份。该股目前由机构投资者持有1.07%的股份。
MiNK Therapeutics Company Profile
水貂治疗公司简介
(Get Rating)
(获取评级)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
明克治疗公司是一家临床阶段的生物制药公司,致力于同种异体、现成、不变的自然杀伤T(INKT)细胞疗法的发现、开发和商业化,以治疗癌症和其他免疫介导性疾病。它的候选产品是AGENT-797,这是一种现成的同种异体药物,用于iNKT细胞治疗和治疗各种骨髓瘤疾病,目前处于第一阶段临床试验。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- Power Integrations Stock Can Power Your Portfolio
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Three Penny Stocks Making Big Moves In November
- 免费获取StockNews.com关于水貂治疗的研究报告(INKT)
- 电源整合股票可以为您的投资组合提供动力
- 不要追逐沃尔玛更高,等待超低价格
- 家得宝的业绩(和机构)是劳氏的催化剂吗?
- 安捷伦在下周第四季度报告发布前仍在买入区间
- 三只细价股在11月大动干戈
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受水貂治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对水貂治疗和相关公司的最新新闻和分析师评级的每日简要摘要。